ClinicalTrials.Veeva

Menu

The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD

Y

Yipeng Liu

Status

Active, not recruiting

Conditions

Thromboembolism
Diabetic Nephropathies
Glomerulonephritis, Membranous
Thrombelastography

Treatments

Other: Grouping based on previous laboratory results, no intervention.

Study type

Observational

Funder types

Other

Identifiers

NCT05656963
YXLL-KY-2022(102)

Details and patient eligibility

About

Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease

Full description

According to the results of renal biopsy, the patients were divided into three groups: membranous nephropathy group (MN), non-membranous nephropathy group (non-MN) and diabetes kidney disease group (DKD). Collect the basic data and TEG test results of the enrolled patients. (1) ① According to TEG results, the enrolled patients were divided into two groups: hypercoagulable group (CI > 3) and non-hypercoagulable group (CI ≤ 3). The basic data and related laboratory indicators of the two groups were compared - to explore the influencing factors of hypercoagulable (objective X); ② Compare the parameters related to TEG and coagulation routine between MN group and non-MN group, DKD group and non-MN group respectively - find out the coagulation index (target Y) of the difference between groups; ③ Build regression models for different target Y - explore the influencing factors of grouping variables (MN vs non MN or DKD vs non MN) on Y after adjusting other covariates; (2) ① According to whether the patients in the group had thrombotic events or not, all the patients in the group with thrombotic events were divided into MN thrombotic events group and non-MN thrombotic events group according to pathological diagnosis, and the TEG, coagulation and other related laboratory results and basic data between the two groups were compared (explore the unique factors and processes that affect the occurrence of thrombotic events in MN group compared with non-MN group); ② According to whether the patients in the MN group who were hospitalized for many times had thrombotic events, the patients were divided into the MN group with thrombotic events and the MN group without thrombotic events. The TEG, coagulation and other related laboratory results and basic data between the two groups were compared (to explore the factors and processes that affect the occurrence of thrombotic events in the MN group).

Enrollment

741 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Primary glomerular disease patients with renal biopsy results (without hormone or immunosuppressive therapy) and patients with clinical diagnosis of diabetes kidney disease;
  2. Age 18-70;
  3. The liver function is normal.

Exclusion criteria

  1. Other secondary kidney diseases except diabetes; Acute renal injury; Chronic kidney disease stage 5;
  2. There are risk factors of hypercoagulability, such as acute infection, recent trauma, surgery or cancer, pregnancy;
  3. Anticoagulant and antiplatelet drugs were given within one week;
  4. Plasma infusion, plasma exchange or hemodialysis within one month;
  5. There is a history of thrombotic disease or hemorrhagic disease before renal puncture;
  6. Participated in other clinical studies within three months.

Trial design

741 participants in 3 patient groups

Idiopathic membranous nephropathy
Description:
Patients with idiopathic membranous nephropathy proved by renal biopsy
Treatment:
Other: Grouping based on previous laboratory results, no intervention.
Non-Idiopathic membranous nephropathy
Description:
Other primary glomerular diseases except membranous nephropathy
Treatment:
Other: Grouping based on previous laboratory results, no intervention.
Diabetic kidney disease
Description:
Patients with clinical diagnosis of diabetes and kidney disease
Treatment:
Other: Grouping based on previous laboratory results, no intervention.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems